CRMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
CorMedix Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$7.38+0.12 (+1.65%)
Close on Oct 19, 2026
- Market cap
- $682.50M
- P/E (TTM)
- 3.6
- Dividend yield
- –
Share price
−$2.80 (−27.50%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
CorMedix Inc. grew revenue 280.5% to $462.25M over the twelve months to Jun 30, 2026. Operating income rose 340.1% to $217.04M, moving the operating margin from 40.6% to 47.0%. Free cash flow was $250.42M, up 723.5% from a year earlier.
Revenue
$462.25M
+280.5% vs. a year earlier
Operating income
$217.04M
+340.1% vs. a year earlier
Free cash flow
$250.42M
+723.5% vs. a year earlier
EPS, diluted
$2.04
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $682.50M
- P/E ratio
- 3.6
- Price to sales
- 1.48
- Price to book
- 1.48
- Dividend yield
- –
- Free cash flow yield
- 36.69%
Fundamentals
- Revenue
- $462.25M
- Net income
- $187.17M
- EPS, diluted
- $2.04
- Free cash flow
- $250.42M
- Book value per share
- $4.98
- Diluted shares
- 92M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$462.25M+280.5% YoY
Gross profit
$382.64M+229.4% YoY
Operating income
$217.04M+340.1% YoY
Net income
$187.17M+265.9% YoY
EPS, diluted
–
Free cash flow
$250.42M+723.5% YoY
Reported periodTrailing twelve months